UY27301A1 - Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata - Google Patents

Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata

Info

Publication number
UY27301A1
UY27301A1 UY27301A UY27301A UY27301A1 UY 27301 A1 UY27301 A1 UY 27301A1 UY 27301 A UY27301 A UY 27301A UY 27301 A UY27301 A UY 27301A UY 27301 A1 UY27301 A1 UY 27301A1
Authority
UY
Uruguay
Prior art keywords
compositions
antiprogestines
treatment
prostate diseases
antiprogestin
Prior art date
Application number
UY27301A
Other languages
English (en)
Inventor
Jens Hoffmann
Rosemarie Lichtner
Ulrike Fuhrmann
Gerhard Siemeister
Martin Schneider
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27301A1 publication Critical patent/UY27301A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos y usos para tratar enfermedades de próstata, en particular cáncer de próstata e hiperplasia benigna de la próstata, en mamíferos macho, con antiprogestinas, en particular, la antiprogestina 11beta - (4-acetilfenil) - 17beta-hidroxi- 17 alfa- (1,1,2,2,2-pentafluoroetil) -estra-4, 9-dien-3-ona, o un derivado o análogo de la misma aceptable para uso farmacéutico. La invención se relaciona además con composiciones farmacéuticas que comprenden dicha antiprogestina.
UY27301A 2001-05-25 2002-05-21 Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata UY27301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01250185 2001-05-25

Publications (1)

Publication Number Publication Date
UY27301A1 true UY27301A1 (es) 2003-02-28

Family

ID=8181589

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27301A UY27301A1 (es) 2001-05-25 2002-05-21 Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata

Country Status (6)

Country Link
EP (1) EP1392399A1 (es)
JP (2) JP2004531561A (es)
AR (1) AR034046A1 (es)
PE (1) PE20021138A1 (es)
UY (1) UY27301A1 (es)
WO (1) WO2002094379A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
DE4039561A1 (de) * 1990-12-07 1992-07-09 Schering Ag Verwendung von antigestagenen zur herstellung von arzneimitteln
DE4318371A1 (de) * 1993-05-28 1994-12-01 Schering Ag Mittel, enthaltend eine Verbindung mit antiandrogener sowie eine Verbindung mit kompetitiver, progesteronantagonistischer Wirkung
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
PL360157A1 (en) * 2000-10-18 2004-09-06 Schering Aktiengesellschaft Use of antiprogestins for the induction of apoptosis in a cell
IL154975A0 (en) * 2000-10-18 2003-10-31 Schering Ag Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases

Also Published As

Publication number Publication date
JP2010077157A (ja) 2010-04-08
EP1392399A1 (en) 2004-03-03
WO2002094379A1 (en) 2002-11-28
PE20021138A1 (es) 2003-01-11
AR034046A1 (es) 2004-01-21
JP2004531561A (ja) 2004-10-14

Similar Documents

Publication Publication Date Title
HUP0100586A2 (hu) Alsó húgyvezetéki tünetek kezelésére alkalmas gyógyászati készítmények
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
HUP9903732A3 (en) Use of cgmp elevators for the preparation of pharmaceutical compositions treating benign prostatic hyperplasia
CY1104981T1 (el) Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
ES2133270T3 (es) Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna.
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
GT199900147A (es) 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
PT1112067E (pt) Utilizacao de inibidores de acetilcolinesterase para a preparacao de composicoes farmaceuticas para o tratamento de sindromas de dor funcional e/ou organica
MXPA03002778A (es) Polipeptidos antiangiogenicos y metodos para inhibir angiogenesis.
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BR0111630A (pt) Espiral para inseto
AU4830097A (en) Use of an extract of Cimicifuga
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
EP1743656A3 (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
UY27301A1 (es) Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
EE200300157A (et) Antiprogestiinide kasutamine apoptoosi esilekutsumiseks rakus
ATE258801T1 (de) Matrixprotein zusammensetzungen um apoptose zu induzieren
ECSP034605A (es) Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
TW200733955A (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141217